Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a sell rating to a hold rating in a research note published on Tuesday morning.

Pieris Pharmaceuticals Trading Up 0.4 %

PIRS stock opened at $16.07 on Tuesday. The company’s 50 day moving average is $16.54 and its two-hundred day moving average is $13.85. Pieris Pharmaceuticals has a twelve month low of $6.20 and a twelve month high of $22.32. The stock has a market cap of $21.21 million, a P/E ratio of -1.33 and a beta of 0.66.

Institutional Trading of Pieris Pharmaceuticals

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. acquired a new position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned 1.21% of Pieris Pharmaceuticals at the end of the most recent quarter. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.